Laron Syndrome Epidemiology Forecast 2025-2034

Laron Syndrome is a rare genetic disorder which is caused by mutations in the growth hormone receptor gene, leading to insensitivity to growth hormone. Insulin-like growth factor 1 (IGF-1), which is necessary for growth and development, is consequently produced at incredibly low levels. Studies suggest the global prevalence of Laron syndrome is approximately 1-9 / 1 000 000.

Laron Syndrome Epidemiology Forecast Report Coverage

The “Laron Syndrome Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of Laron syndrome. It projects the future incidence and prevalence rates of Laron syndrome across various populations. The study covers age and type as major determinants of the Laron syndrome-affected population. The report highlights patterns in the prevalence of Laron syndrome over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of Laron syndrome in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Laron Syndrome: Disease Overview

Laron syndrome is a rare autosomal recessive disorder caused by mutations in the growth hormone receptor gene. Short stature, characteristic facial features (small jaw, saddle nose, and prominent forehead), delayed puberty, and obesity despite decreased muscle mass are some of the defining characteristics of the condition. Notably, people with Laron syndrome are much less likely to develop type 2 diabetes and cancer, most likely as a result of decreased IGF-1 activity. Genetic testing and hormone level measurement are used for diagnosis.

Laron Syndrome: Treatment Overview

Recombinant insulin-like growth factor-1 (IGF-1) therapy is the primary treatment for Laron syndrome. It helps improve metabolism, encourage linear growth, and address certain developmental delays. In order to optimize growth potential, IGF-1 is usually injected subcutaneously beginning in early childhood. The underlying growth hormone receptor defect renders growth hormone therapy ineffective. Even though some clinical characteristics, like short stature, may not go away with therapy, early diagnosis and treatment are essential for the best results.

Epidemiology

The Laron syndrome epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for Laron syndrome by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for Laron syndrome and their trends. The data is broken down into specific categories, such as the total diagnosed cases across different age groups and patient pools.

• According to the National Institute of Health, Southern Ecuador and the Mediterranean region have reported the majority of cases, with a small number from South America.
• According to the U.S. Department of Health & Human Services, less than 5,000 people in the United States have this disease.

Country-wise Laron Syndrome Epidemiology

The Laron Syndrome epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

Laron syndrome is a rare autosomal recessive disorder. Its distribution is uneven across nations, with isolated populations with a higher rate of consanguinity having the highest prevalence. Laron syndrome is extremely rare in regions like America, Europe, and Asia, with cases most often found in specific communities with higher rates of genetic isolation or consanguinity. The overall incidence in these continents is likely less than in regions like Ecuador and parts of the Middle East.

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification of Laron syndrome based on several factors.
• Laron Syndrome Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The report helps to identify the patient population, and the unmet needs of Laron syndrome are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of Laron syndrome epidemiology in the 8 major markets?
• What will be the total number of patients with Laron syndrome across the 8 major markets during the forecast period?
• What was the country-wise prevalence of Laron syndrome in the 8 major markets in the historical period?
• Which country will have the highest number of Laron syndrome patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of Laron syndrome during the forecast period of 2025-2034?
• What are the currently available treatments for Laron syndrome?
• What are the disease risks, signs, symptoms, and unmet needs of Laron syndrome?

This product will be delivered within 3-5 business days.